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Natural Killer (NK) cell function is regulated by an array of inhibitory and activating surface
receptors that during NK cell differentiation, at variance with T and B cells, do not require
genetic rearrangement. Importantly, NK cells are the first lymphocyte population recover-
ing after hematopoietic stem cell transplantation (HSCT).Thus, their role in early immunity
after HSCT is considered crucial, as they can importantly contribute to protect the host
from tumor recurrence and viral infections before T-cell immunity is fully recovered. In
order to acquire effector functions and regulatory receptors, NK cell precursors undergo
a maturation process that can be analyzed during immune reconstitution after HSCT. In
this context, the occurrence of human cytomegalovirus (HCMV) infection/reactivation was
shown to accelerate NK cell maturation by promoting the differentiation of high frequen-
cies of NK cells characterized by a KIR+NKG2A− and NKG2C+ mature phenotype. Thus,
it appears that the development of NK cells and the distribution of NK cell receptors can
be deeply influenced by HCMV infection. Moreover, in HCMV-infected subjects the emer-
gence of so called “memory-like” or “long-lived” NK cells has been documented. These
cells could play an important role in protecting from infections and maybe from relapse
in patients transplanted for leukemia. All the aspects regarding the influence of HCMV
infection on NK cell development will be discussed.
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INTRODUCTION
Natural killer (NK) cells represent crucial effectors in innate
immune response to viral infections and tumors. NK cell function
is regulated by an array of germline-encoded surface receptors,
that, upon interaction with their ligands, transmit either inhibitory
or activating signals (1–3).
Most human NK cells express inhibitory receptors specific
for HLA-class I molecules, including the Killer Ig-like Receptors
(KIRs),able to distinguish among different HLA-A,-B,and -C allo-
types (4), and the CD94/NKG2A heterodimer, specific for HLA-E
(5). These receptors allow NK cells to spare HLA-class I+ autolo-
gous normal cells and to kill cells in which HLA class I expression is
down-regulated (e.g., by tumor transformation or viral infection)
or cells expressing non-self HLA class I alleles unable to engage
inhibitory KIRs (e.g., in the allogeneic transplant settings).
Activating counterparts of the inhibitory receptors specific for
HLA class I molecules can be expressed by NK cells. In particu-
lar, activating KIRs, including KIR2DS1, KIR2DS2, and KIR3DS1,
are highly homologous to their inhibitory counterparts in the
extracellular domain, but are characterized by a short cytoplasmic
tail lacking Immunoreceptor Tyrosine-Based Inhibitory Motifs
(ITIM). On the other hand, activating KIRs interact with DAP-
12, an adaptor signaling molecule carrying an Immunoreceptor
Tyrosine-Based Activating Motif (ITAM) that can induce NK cell
activation (6). So far, the HLA class I specificity of activating KIRs
has been clearly demonstrated only for KIR2DS1 and KIR2DS4
(6–8). KIR genes are located on chromosome 19 and are inher-
ited as haplotypes. Two basic KIR haplotypes can be found in the
human genome: group A haplotypes, which have a fixed number
of genes that encode inhibitory receptors (with the exception of
the activating receptor KIR2DS4) and group B haplotypes, which
have variable gene content, including additional activating KIR
genes (4, 9).
Another HLA class I-specific activating receptor is represented
by the HLA-E-specific CD94/NKG2C heterodimer. At variance
with its inhibitory counterpart CD94/NKG2A, which contains
an ITIM in the NKG2A cytoplasmic domain, NKG2C, like the
activating KIRs, lacks ITIM and is associated with DAP-12 (9).
Human NK cells mainly differentiate in the bone marrow (BM)
from CD34+ hematopoietic stem cells (HSCs) through discrete
stages of development. However, recent studies suggest that differ-
ent sites, such as secondary lymphoid compartments (SLCs) (10),
human decidua (11), thymus (12), or fetal and adult liver (13)
can be involved in this process. Two main subsets of mature NK
cells with distinct functional and phenotypic properties have been
described: the CD56bright CD16−/low and the CD56dim CD16+
subsets. CD56bright NK cells typically express high levels of the
receptor CD94/NKG2A, but low levels of KIR molecules. They are
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not abundant in peripheral blood, while dominate in SLCs for
which they express specific homing receptors. CD56bright NK cells
produce high levels of immunoregulatory cytokines,but are poorly
cytotoxic. In contrast, the CD56dim subset is characterized by
high surface expression of KIR receptors, is largely represented in
peripheral blood and is highly cytotoxic against tumor and virus-
infected targets (14). A recent study shows that CD56dim NK cells
may also release high amounts of IFN-γ very early after activation
(15). In addition, a third subset, characterized by a CD56−CD16+
surface phenotype, exists,but is rare in healthy individuals and rep-
resents a small percentage of total NK cells. However, expansion of
CD56− NK cells have been described in HIV and HCV chronically
infected subjects (16, 17) and also in recipients of hematopoietic
stem cell transplantation (HSCT) (18, 19).
The developmental relationship between CD56bright and
CD56dim has been long debated; however, recent reports sug-
gest that CD56dim derive from CD56bright cells. Thus, it has been
shown that in CD56brightCD16− cells telomeres are significantly
longer than in CD56dimCD16bright cells (20). In addition, when
CD56bright NK cells were infused in NOD/SCID mice, they pro-
gressed toward the CD56dim phenotype (21). In line with these
observations the first wave of NK cells that reconstitute after HSCT
is represented by the CD56bright NK cell subset. Only later on
CD56dim NK cells appear in the blood and are initially character-
ized by high CD94/NKG2A expression. The complete maturation
of CD56dim NK cells involve the progressive loss of CD94/NKG2A
and the acquisition of combinations of KIR molecules, in order
to form a relatively stable repertoire which is mainly genetically
determined, but influenced by the HLA class I genotype (4, 22–25).
During their late stages of differentiation,NKG2A−KIR+CD56dim
NK cells progressively acquire a CD57+ CD94low CD62Lneg phe-
notype (26–29). In order to become fully competent NK cells
have been shown to require recognition of self HLA class I mole-
cules during maturation, a phenomenon referred to as “licensing”
or “education” (30–32). However, unlicensed NK cells lacking
inhibitory receptors specific for self HLA molecules (either KIR
or NKG2A/CD94) do exist, but are hyporesponsive (31, 33). Thus,
in a self environment the NK cell receptor repertoire will ensure
self tolerance as each functional NK cell expresses at least one
inhibitory receptor specific for self HLA-I molecules. In contrast,
in allogeneic settings, NK cells may kill allogeneic cells express-
ing HLA-I non-self molecules. The existence of “alloreactive” NK
cells can be particularly important in HSCT (34). Since HSCT is
a widely employed treatment used to cure malignant disorders
such as acute leukemia, these alloreactive NK cells can greatly
contribute to the eradication of residual tumor cells (Graft vs.
Leukemia effect), prevent Graft vs. Host Disease (GvHD), and
improve engraftment by the killing of recipient dendritic cells
(DC) and T-cells, respectively (35, 36).
NK CELL RESPONSES TO HCMV INFECTION
Natural killer cells can importantly contribute to immune
responses against viral infections. Indeed, in patients with NK
cell deficiency a higher susceptibility to herpesvirus infections has
been observed (37–39).
Human cytomegalovirus (HCMV) is a β-herpesvirus
that establishes a lifelong persistent infection (40). In
immunocompetent hosts, HCMV infection is usually asympto-
matic, but reactivation becomes an important cause of morbidity
in primary or acquired immunodeficiencies and immunosup-
pressed patients particularly in transplant recipients. In healthy
individuals both T-cell and NK cells are involved in controlling
HCMV infection (41).
During the host-HCMV interplay, NK cells are likely to receive
stimuli from infected cells or other immune cells that can mod-
ulate their phenotype and function. In particular it has been
shown that HCMV is capable of shaping the NK cell receptor
repertoire inducing the expansion of an NK cell subset express-
ing the activating NKG2C receptor. Remarkably, this expanded
NKG2C+ NK cell subset found in HCMV seropositive indi-
viduals is also characterized by a mature phenotype, mostly
KIR+NKG2A− (42). This finding was observed both in healthy
individuals and in patients with different pathological condi-
tions. Indeed, increased proportions of KIR+NKG2A−NKG2C+
NK cells have been described in subjects who experienced differ-
ent viral infections, including HIV (43, 44), Chikungunya virus
(45), Hantavirus (46), HBV and HCV (47). However, it is con-
ceivable that HCMV infection/reactivation, which may occur in
chronically infected subjects, may be responsible for the induction
of such NK cell phenotype in these patients. NKG2C+KIR+ NK
cell expansions have been described also in congenital immunod-
eficiencies where this NK cell subset has been proposed to play a
relevant role in the resolution of HCMV infection (48). Together,
these data suggest that the NKG2C receptor could play a cru-
cial role in HCMV recognition and in promoting the expansion
and/or maturation of NKG2C+ cells, as well as in the control of
infection.
The mechanism responsible for the NK cell expansion
described is still unclear. It has been suggested that NK cells could
be stimulated by HCMV-infected targets, through the heterodimer
CD94/NKG2C. In this context, HCMV-infected fibroblasts have
been shown to favor the expansion of NKG2C+ NK cells, cultured
in the presence of either IL-15 or IL-2. MAb-mediated mask-
ing of CD94 could inhibit this selective expansion (49). Other
studies reported that NKG2C+ NK cells can undergo prolifer-
ation when co-cultured with HLA-E-transfected 721.221 lym-
phoblastoid cells (50, 51) or K562 cell lines (46). It is possible
that HCMV-infected targets may express ligands interacting with
NKG2C+ NK cells, thus inducing their activation and prolifera-
tion. Remarkably, the signal peptide of the HCMV UL40 protein
stabilizes HLA-E expression on HCMV-infected fibroblasts, while
other HCMV-derived peptides (including US2, US3, US6, US10,
and US11) dampen the surface expression of classical HLA class I
molecules (52). These observations suggest that, during the inter-
action with HCMV-infected cells, the expansion of mature NK
cells expressing inhibitory self KIRs could be favored because of
the lack of inhibitory interactions with classical HLA class I mol-
ecules. Moreover, the stabilization of HLA-E, while favoring the
expansion of NKG2C+ cells, would inhibit that of cells expressing
NKG2A. This is in line with a recent study showing that a past
HCMV infection in healthy individuals is strongly correlated with
expansion of NKG2C+ NK cells expressing inhibitory self KIRs
(i.e., educated NK cells expressing KIRs specific for self HLA class
I molecules) (51).
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However, direct evidence for the specificity of NKG2C for HLA-
E molecules loaded with viral peptides, or for an unknown ligand
of either host or viral origin expressed by HCMV-infected cells is
missing or limited. It would be important to analyze the peptides
that in vivo are bound to HLA-E in HCMV-infected cells and to
verify their role in inducing NKG2C-mediated NK cell recogni-
tion. In this context, by the analysis of HCMV UL40 sequences
isolated from HSCT recipients undergoing HCMV reactivation,
it has been shown that UL40 is characterized by a certain degree
of polymorphism that could modulate NK cell-mediated recogni-
tion of HCMV-infected targets. In particular, some UL40 peptides
derived from the signal sequence (i.e., HLA-E-binding peptides)
encoded by HCMV isolates, are capable of both inhibiting NK
cell lysis by NKG2A engagement and inducing NK cell activation
through NKG2C triggering, whereas other forms of UL40 peptides
do not stimulate NKG2C+ cells, but are still capable of inducing
inhibitory responses via NKG2A (53). Whether such UL40 poly-
morphisms can affect the expansion of NK cells expressing NKG2C
and/or virus clearance in HCMV-infected HSCT recipients is
unknown.
Human NK cell responses to HCMV can also be elicited
through direct recognition of HCMV virions by NK cells (54).
After exposure to HCMV, NK cells become activated and pro-
duce IFN-γ. This anti-HCMV response involves the engagement
of TLR2 on NK cells by viral particles and the endogenous release
of IFN-β. However, direct recognition of HCMV is not sufficient
to induce stable changes in NK cell receptor repertoire.
HCMV DRIVES NK CELL MATURATION TOWARD HIGHLY
DIFFERENTIATED STAGES IN HSCT RECIPIENTS
The imprinting on NK cell phenotype induced by HCMV infection
results particularly dramatic when T-cell immunity is impaired in
the infected host, such as in chronically infected HIV patients
(43, 44), congenitally immunodeficient individuals (48, 55) and
patients undergoing HSCT.
In this context, two recent studies have shown that HCMV reac-
tivation can promote a rapid NK cell development after umbilical
cord blood transplantation (UCBT) (56, 57). NK cells achieved
a full maturation more rapidly in HCMV-reactivating patients
as compared to non-infected ones. In particular, NK cells iso-
lated from HCMV-reactivating patients show low percentages of
CD56bright NK cell and high proportions of mature CD56dim NK
cells expressing the NKG2C+ NKG2A− KIR+ Siglec-7− CD57+
signature, at variance with non-reactivating patients that dis-
play a more immature phenotype (57). NKG2C+ CD56dim NK
cells were characterized by the expression of self-KIR and dis-
played full competence in terms of cytolytic activity and cytokine
production. The frequency of mature KIR+NKG2C+ NK cells
persisted and continued to increase after 1 year from HSCT in
recipients who reactivated HCMV. This expanded and long-living
NKG2C+ NK cell subset is clearly reminiscent of a population
of Ly49H+ NK cells which expands in murine CMV (MCVM)
infected mice and is responsible for disease clearance through the
induction of a “memory-like” NK cell response. Thus, NKG2C+
NK cells, expanding after HCMV infection, could represent the
human counterpart of murine “memory-like” NK cells. However,
a clear recall response against HCMV-infected targets, mediated
by human NKG2C+ NK cells, has not been shown yet.
Importantly, in mouse, the Ly49H receptor has been demon-
strated to bind to the MCMV protein m157 which is expressed by
infected cells (58).
The mechanisms lying behind this accelerated maturation and
expansion of KIR+NKG2C+ NK cells after HSCT are not com-
pletely understood. As already discussed, developing NK cells
could be stimulated by HCMV-infected targets, possibly through
the heterodimer CD94/NKG2C. HCMV infection could exert
its influence on NK cell development at different sites and/or
stages of maturation (Figure 1). First, NK cell precursors could
be stimulated by HCMV while differentiating in the BM where
they may interact with cells of the myeloid lineage that can
be infected by HCMV and that represent a reservoir of latent
virus (41). Second, CD56bright NK cells, that are characterized by
the expression of the lymph node homing chemokine receptor
CCR7 (59), can reach SLC (e.g., lymph node) and interact with
infected antigen-presenting cells, DC, or macrophages, that would
promote NK cell differentiation toward more mature CD56dim
stages. A third possibility is that circulating CD56dim NK cells
could migrate to peripheral tissues (59) (e.g., mucosal tissues)
where HCMV infection can affect different cell types (fibrob-
lasts, endothelial cells, epithelial cells) (41). In this microenviron-
ment, NK cells would receive, directly or indirectly, proliferating
and maturing signals from infected targets that would drive NK
cells toward highly differentiated stages of maturation, charac-
terized by the KIR+ NKG2C+ NKG2A− signature. This last sce-
nario better corresponds to in vitro data showing that CD56dim
NK cells proliferate in response to HCMV-infected fibroblasts
(49). However, it is not clear so far whether this expanded
NKG2C+KIR+NKG2A−Siglec-7− NK cell subset, developed in
response to HCMV-derived stimuli, represents a long-living cell
subset or is rather continuously replenished by novel mature
NK cells.
Remarkably, in HCMV-reactivating patients a unusual
CD56−CD16+Siglec-7− NK cell subset was detected (57) that was
reminiscent of that described in viremic HIV-infected patients
undergoing HCMV reactivation (60). The similarity between
CD56− NK cells found in HCMV-infected UCBT recipients and
those present in HIV-infected patients was also confirmed by a
marked impairment in functional capabilities. This may be con-
sequent, at least in part, to the low expression on CD56− cells
of several activating receptors such as NCRs and NKG2D, as also
reported in chronically HIV-infected patients. It is conceivable that
these hyporesponsive CD56− NK cells are generated after HCMV
infection when T-cell immunity is impaired. The accumulation of
these phenotypically aberrant and hypofunctional NK cells could
also support the concept that HCMV has a role in immunosenes-
cence (61). However, it should be noted that, in HSCT recipients,
the hypofunctional state of CD56− NK cells could be reversed by
exposure to exogenous cytokines, such as IL-2. This observation
would suggest that the generation of these cells can be consequent
to chronic stimulation together with lack of appropriate T-cell
responses and cytokine production rather than to an irreversible
process of aging induced by HCMV.
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FIGURE 1 | Human cytomegalovirus accelerates NK cell maturation
after HSCT: possible sites of NK cell-HCMV interplay. Schematic
representation of NK cell maturation from CD34+ HSC in recipients
reactivating HCMV. NK cell development is rapidly driven toward a mature
stage of differentiation characterized by a KIR+NKG2A−NKG2C+CD57+
Siglec-7− surface phenotype. The signals driving NK cell maturation might
be provided at different developmental stages in different sites: in (A) it is
hypothesized that during NK cell differentiation in the bone marrow, NK cell
precursors could interact with HCMV-infected myeloid cells; in (B) CD56bright
NK cells that express CCR7 can reach the secondary lymphoid
compartment (SLC) where they could interact with HCMV-infected stromal
cells, dendritic cells, or macrophages (Mφ); in (C) circulating CD56dim
NKG2A+ NK cells could migrate to peripheral tissues and interact with
HCMV-infected fibroblasts or endothelial cells.
A distinguishing feature of both CD56dim and CD56− NK
cells observed in HCMV-infected recipients is the dramatic down-
regulation of Siglec-7. Although the mechanism/significance of
this event is unknown, it represents, together with NKG2C up-
regulation, the most typical marker of NK cell expansions pro-
moted by HCMV infection. Whether Siglec-7 down-regulation
could be a marker of “memory-like” NK cells has still to be
investigated.
Human cytomegalovirus-induced NK cell populations with a
“memory-like” surface phenotype may contribute not only to the
control of virus infection, but also to the protection from leukemia
relapses after HSCT. In this context, a recent study reported a
correlation between early HCMV reactivation and reduction of
leukemia relapse after allogeneic HSCT in adult patients (62). The
HCMV-induced rapid maturation of functional NK cells could
favor an NK cell-mediated anti-leukemic activity, especially in the
case of a KIR-mismatched haplo-HSCT in which the fast differ-
entiation of mature KIR+NKG2A− NK cells could promote the
emergence of anti-leukemic alloreactive NK cells.
“Memory-like”NKG2C+NK cells have been also demonstrated
to be transplantable employing unmanipulated adult grafts from
HCMV seropositive donors (63). These donor-derived NK cells,
contained in the graft, expanded not only in recipients under-
going HCMV reactivation, but also in seropositive recipients in
the absence of detectable viremia. These NKG2C+ NK cells were
capable of producing higher levels of IFN-γ as compared to
NKG2C+ NK cells infused in seronegative recipients, suggest-
ing that a subsequent exposure to viral antigens in the recipient
can increase cytokine production, by inducing a “memory-like”
response that might contribute to control of HCMV reactivation
in these HCMV+ recipients. Of note, a recent paper suggested
that NK cells exposed to multiple cytokines (a circumstance which
likely occurs during an anti-viral immune response) can acquire
a “memory-like” phenotype and would release higher amounts of
IFN-γ following restimulation with cytokines or target cells (64).
NKG2C thus seems to play a central role in HCMV-induced
responses by NK cells; however, recent reports indicated that also
other NK receptors may be involved and that NKG2C could be
dispensable. For example, in a cohort of children with or without
congenital HCMV infection the deletion of one or two copies of
NKG2C did not correlate with a higher incidence of HCMV infec-
tion (65). Further supporting the concept that NK receptors other
than NKG2C can contribute to shape NK cell receptor repertoire,
following HCMV infection, is a study reporting the expansion
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of NKG2A−NKG2C− NK subsets expressing activating KIRs in a
cohort of HCMV seropositive healthy individuals (51). In this con-
text, a number of studies suggested that the presence of activating
KIRs is protective against viral infections (66–69).
CONCLUDING REMARKS
The development of NK cells reconstituting after transplanta-
tion can be profoundly affected by HCMV infection/reactivation,
which is a common event in immunocompromised HSCT recipi-
ents. Although HCMV infection is cause of morbidity and mortal-
ity in such patients, it can also promote NK cell differentiation by
accelerating the acquisition of a fully mature KIR+ NKG2A− phe-
notype. Notably, in the case of KIR-mismatched haplo-HSCT, this
phenomenon may be of particular benefit, since it results in rapid
expansion of alloreactive NK cells (characterized in all instances
by the KIR+NKG2A− phenotype). These mature NK cells can
display not only anti-leukemia activity but also important anti-
viral activity that could be beneficial to HSCT recipients. Finally,
the strong imprinting induced by HCMV on developing NK cells
could be (cautiously) harnessed to design new adoptive NK cell
based therapies.
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